Mutational status of myeloproliferative neoplasms

Elisa Rumi, Chiara Elena, Francesco Passamonti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Philadelphia negative myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Altered signaling is a hallmark of myeloproliferative neoplasms, as demonstrated by the presence of activating JAK2 (V617F) mutation in about 70% of patients (95% of polycythemia vera, 50%-60% of essential thrombocythemia, and 50%-60% of primary myelofibrosis). How a unique point mutation can cause three different phenotypes remains to be clarified. The oncogenic potential of this mutation has been documented by mouse models, and different clinical studies have demonstrated an effect of mutant allele burden on phenotype. Mutant allele burden, in fact, directly correlates with hemoglobin value, leukocyte count, and, inversely, with platelet count. The molecular basis of JAK2 (V617F)-negative myeloproliferative neoplasms remains largely unexplained. Additional mutations in MPL, TET2, and CBL genes have been found in a small proportion of these patients. Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review.

Original languageEnglish
Pages (from-to)61-76
Number of pages16
JournalCritical Reviews in Eukaryotic Gene Expression
Volume20
Issue number1
Publication statusPublished - 2010

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Mutation
Phenotype
Neoplasms
Alleles
Platelet Count
Leukocyte Count
Point Mutation
Hemoglobins
Genes
Clinical Studies

Keywords

  • CBL
  • JAK2
  • MPL
  • Myelofi brosis
  • Polycythemia
  • TET2
  • Thrombocythemia

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology

Cite this

Mutational status of myeloproliferative neoplasms. / Rumi, Elisa; Elena, Chiara; Passamonti, Francesco.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 20, No. 1, 2010, p. 61-76.

Research output: Contribution to journalArticle

@article{6ae254c8da3446249f834dbc01862708,
title = "Mutational status of myeloproliferative neoplasms",
abstract = "Philadelphia negative myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Altered signaling is a hallmark of myeloproliferative neoplasms, as demonstrated by the presence of activating JAK2 (V617F) mutation in about 70{\%} of patients (95{\%} of polycythemia vera, 50{\%}-60{\%} of essential thrombocythemia, and 50{\%}-60{\%} of primary myelofibrosis). How a unique point mutation can cause three different phenotypes remains to be clarified. The oncogenic potential of this mutation has been documented by mouse models, and different clinical studies have demonstrated an effect of mutant allele burden on phenotype. Mutant allele burden, in fact, directly correlates with hemoglobin value, leukocyte count, and, inversely, with platelet count. The molecular basis of JAK2 (V617F)-negative myeloproliferative neoplasms remains largely unexplained. Additional mutations in MPL, TET2, and CBL genes have been found in a small proportion of these patients. Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review.",
keywords = "CBL, JAK2, MPL, Myelofi brosis, Polycythemia, TET2, Thrombocythemia",
author = "Elisa Rumi and Chiara Elena and Francesco Passamonti",
year = "2010",
language = "English",
volume = "20",
pages = "61--76",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "1",

}

TY - JOUR

T1 - Mutational status of myeloproliferative neoplasms

AU - Rumi, Elisa

AU - Elena, Chiara

AU - Passamonti, Francesco

PY - 2010

Y1 - 2010

N2 - Philadelphia negative myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Altered signaling is a hallmark of myeloproliferative neoplasms, as demonstrated by the presence of activating JAK2 (V617F) mutation in about 70% of patients (95% of polycythemia vera, 50%-60% of essential thrombocythemia, and 50%-60% of primary myelofibrosis). How a unique point mutation can cause three different phenotypes remains to be clarified. The oncogenic potential of this mutation has been documented by mouse models, and different clinical studies have demonstrated an effect of mutant allele burden on phenotype. Mutant allele burden, in fact, directly correlates with hemoglobin value, leukocyte count, and, inversely, with platelet count. The molecular basis of JAK2 (V617F)-negative myeloproliferative neoplasms remains largely unexplained. Additional mutations in MPL, TET2, and CBL genes have been found in a small proportion of these patients. Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review.

AB - Philadelphia negative myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and primary myelofibrosis. Altered signaling is a hallmark of myeloproliferative neoplasms, as demonstrated by the presence of activating JAK2 (V617F) mutation in about 70% of patients (95% of polycythemia vera, 50%-60% of essential thrombocythemia, and 50%-60% of primary myelofibrosis). How a unique point mutation can cause three different phenotypes remains to be clarified. The oncogenic potential of this mutation has been documented by mouse models, and different clinical studies have demonstrated an effect of mutant allele burden on phenotype. Mutant allele burden, in fact, directly correlates with hemoglobin value, leukocyte count, and, inversely, with platelet count. The molecular basis of JAK2 (V617F)-negative myeloproliferative neoplasms remains largely unexplained. Additional mutations in MPL, TET2, and CBL genes have been found in a small proportion of these patients. Implications of these mutations in the understanding of the pathogenesis of myeloproliferative neoplasms and in the clinical phenotype are discussed in this review.

KW - CBL

KW - JAK2

KW - MPL

KW - Myelofi brosis

KW - Polycythemia

KW - TET2

KW - Thrombocythemia

UR - http://www.scopus.com/inward/record.url?scp=77953850873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953850873&partnerID=8YFLogxK

M3 - Article

C2 - 20528738

AN - SCOPUS:77953850873

VL - 20

SP - 61

EP - 76

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 1

ER -